Hengrui Pharma(SH:600276) 天天基金网·2025-05-26 11:26Group 1 - The article highlights a surge in A-share listed companies opting for listings in Hong Kong, with Heng Rui Medicine being the latest to join, marking the fourth "AH" stock of the year [1] - Heng Rui Medicine's stock price soared by 25.20% on its debut, achieving a market capitalization of HKD 364.2 billion [1] - The article notes that over twenty A-share companies have submitted prospectuses to the Hong Kong Stock Exchange, with five currently approved by the China Securities Regulatory Commission [1] Group 2 - Industry insiders suggest that more companies are using the Hong Kong platform to connect with international capital and align with global valuation systems, reflecting a trend of capital markets moving from local to global [2] - This wave of listings is characterized by a proactive approach, with companies like Ningde Times choosing Hong Kong to expand their growth strategies, indicating a strategic commitment to globalization [2] - The article emphasizes that Hong Kong is gradually becoming a core platform for the discovery of Chinese asset values [2]